Cassiopea SPA: peers
Cassiopea SPA beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Cassiopea SPA, Atrys Health, S.A., Newron Pharmaceuticals, Genenta Science S.P.A.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Cassiopea SPAbase SKIN.SW · 🇮🇹 IT Percentile in Healthcare Percentile in Italy | Atrys Health, S.A. ATRY.MC · 🇪🇸 ES Percentile in Healthcare Percentile in Spain | Newron Pharmaceuticals NP5.F · 🇮🇹 IT Percentile in Healthcare Percentile in Italy | Genenta Science S.P.A. GNTA · 🇮🇹 IT Percentile in Healthcare Percentile in Italy | ARS Pharmaceuticals, Inc. SPRY · 🇺🇸 US Percentile in Healthcare Percentile in USA | Fennec Pharmaceuticals Inc. FENC · 🇺🇸 US Percentile in Healthcare Percentile in USA | C4 Therapeutics, Inc. CCCC · 🇺🇸 US Percentile in Healthcare Percentile in USA | Nautilus Biotechnology, Inc. NAUT · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $380 Mlast known, Jan 7, 2022 · Market dataLast known value: no current one2nd of 8 | $312 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one6th of 8 | $190 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one7th of 8 | $63 MAug 1, 2026 · Market data8th of 8 | $375 MOct 28, 2026 · Market data3rd of 8 | $374 MOct 31, 2026 · Market data4th of 8 | $391 MOct 27, 2026 · Market data1st of 8 | $368 MOct 28, 2026 · Market data5th of 8 | $371 M8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | $159 MFY2025 · ESEF1st of 4 | —— | —— | $84 MFY2025 · SEC2nd of 4 | $45 MFY2025 · SEC3rd of 4 | $36 MFY2025 · SEC4th of 4 | —— | $64 M4 ranked |
| Net income (Higher is better) | —— | $-113 MFY2025 · ESEF5th of 6 | —— | $-7 MFY2025 · SEC1st of 6 | $-171 MFY2025 · SEC6th of 6 | $-10 MFY2025 · SEC2nd of 6 | $-105 MFY2025 · SEC4th of 6 | $-59 MFY2025 · SEC3rd of 6 | $-82 M6 ranked |
| Employees (Better neither way: ranked highest first) | —— | —— | —— | —— | 158December 31, 2025 · Profile1st of 4 | 35December 31, 2025 · Profile4th of 4 | 121As on 2021 · Profile3rd of 4 | 130December 31, 2025 · Profile2nd of 4 | 1264 ranked |
| Growth | |||||||||
| Market cap change, 30 days (Higher is better) | —— | —— | —— | —— | —— | -2.2%30 days to Oct 31, 2026 · Market data1st of 2 | -10.0%30 days to Oct 27, 2026 · Market data2nd of 2 | —— | -6.1%2 ranked |
| Revenue growth (Higher is better) | ———— | +13.0%FY2025 · ESEF1st of 456th68th | ———— | ———— | -5.5%FY2025 · SEC3rd of 417th17th | -6.1%FY2025 · SEC4th of 416th16th | +1.0%FY2025 · SEC2nd of 428th32nd | ———— | -2.2%4 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | ———— | ———— | ———— | ———— | +207.2%FY2025 · SEC1st of 299th100th | +5.0%FY2025 · SEC2nd of 241st53rd | ———— | +106.1%2 ranked |
| Margins and returns | |||||||||
| Operating margin (Higher is better) | ———— | -29.6%FY2025 · ESEF2nd of 438th6th | ———— | ———— | -212.9%FY2025 · SEC3rd of 415th5th | -14.1%FY2025 · SEC1st of 444th24th | -320.5%FY2025 · SEC4th of 411th4th | ———— | -121.3%4 ranked |
| Net margin (Higher is better) | ———— | -71.1%FY2025 · ESEF2nd of 427th2nd | ———— | ———— | -203.3%FY2025 · SEC3rd of 415th6th | -21.8%FY2025 · SEC1st of 441st21st | -292.0%FY2025 · SEC4th of 411th4th | ———— | -137.2%4 ranked |
| Free cash flow margin (Higher is better) | ———— | -5.7%FY2025 · ESEF1st of 344th23rd | ———— | ———— | -203.1%FY2025 · SEC2nd of 315th5th | ———— | -276.2%FY2025 · SEC3rd of 313th3rd | ———— | -203.1%3 ranked |
| Return on equity (Higher is better) | ———— | -51.2%FY2025 · ESEF4th of 643rd3rd | ———— | -38.1%FY2025 · SEC2nd of 650th2nd | -92.3%FY2025 · SEC6th of 627th11th | -65.8%FY2025 · SEC5th of 635th15th | -44.4%FY2025 · SEC3rd of 646th20th | -32.3%FY2025 · SEC1st of 652nd23rd | -47.8%6 ranked |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | ———— | 185.1×price Oct 31, 2026 · Market dataonly one with it95th97th | ———— | ———— | 185.1×— |
| Price to sales (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | 3.1×price Oct 28, 2026 · Market data3rd of 344th61st | 5.6×price Oct 31, 2026 · Market data2nd of 360th79th | 12.1×price Oct 27, 2026 · Market data1st of 376th91st | ———— | 5.6×3 ranked |
| Price to book (Better neither way: ranked highest first) | ———— | ———— | ———— | 2.5׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 3.3×price Oct 28, 2026 · Market data2nd of 453rd65th | 10.5×price Oct 31, 2026 · Market data1st of 484th90th | 1.5×price Oct 27, 2026 · Market data4th of 431st37th | 2.4×price Oct 28, 2026 · Market data3rd of 441st53rd | 2.8×4 ranked |
| Free cash flow yield (Higher is better) | ———— | ———— | ———— | -12.3%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | -45.7%price Oct 28, 2026 · Market data4th of 420th8th | -0.6%price Oct 31, 2026 · Market data1st of 466th35th | -25.4%price Oct 27, 2026 · Market data3rd of 429th13th | -14.1%price Oct 28, 2026 · Market data2nd of 438th18th | -19.8%4 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | ———— | ———— | ———— | 0.8×FY2025 · SEConly one with it71st62nd | ———— | ———— | ———— | 0.8×— |
| Interest cover (Higher is better) | ———— | ———— | ———— | ———— | ———— | -3.0×FY2025 · SEConly one with it61st35th | ———— | ———— | -3.0×— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | 2 of 5FY2025 · Scorecard1st of 6 | —— | 0 of 6FY2025 · Scorecard6th of 6 | 5 of 18FY2025 · Scorecard3rd of 6 | 8 of 20FY2025 · Scorecard1st of 6 | 4 of 21FY2025 · Scorecard5th of 6 | 3 of 12FY2025 · Scorecard4th of 6 | 26% passed6 ranked |
| Valuation checks (Higher is better) | —— | —— | —— | —— | 1 of 5FY2025 · Scorecard2nd of 4 | 1 of 5FY2025 · Scorecard2nd of 4 | 1 of 5FY2025 · Scorecard2nd of 4 | 1 of 4FY2025 · Scorecard1st of 4 | 20% passed4 ranked |
| Growth checks (Higher is better) | —— | 1 of 2FY2025 · Scorecard2nd of 6 | —— | 0 of 2FY2025 · Scorecard4th of 6 | 0 of 3FY2025 · Scorecard4th of 6 | 3 of 5FY2025 · Scorecard1st of 6 | 1 of 5FY2025 · Scorecard3rd of 6 | 0 of 2FY2025 · Scorecard4th of 6 | 10% passed6 ranked |
| Profitability checks (Higher is better) | —— | 1 of 3FY2025 · Scorecard2nd of 6 | —— | 0 of 2FY2025 · Scorecard5th of 6 | 1 of 5FY2025 · Scorecard3rd of 6 | 2 of 5FY2025 · Scorecard1st of 6 | 1 of 5FY2025 · Scorecard3rd of 6 | 0 of 3FY2025 · Scorecard5th of 6 | 20% passed6 ranked |
| Financial health checks (Higher is better) | —— | —— | —— | 0 of 1FY2025 · Scorecard5th of 5 | 2 of 4FY2025 · Scorecard1st of 5 | 2 of 4FY2025 · Scorecard1st of 5 | 1 of 3FY2025 · Scorecard4th of 5 | 1 of 2FY2025 · Scorecard1st of 5 | 50% passed5 ranked |
| Shareholder returns checks (Higher is better) | —— | —— | —— | 0 of 1FY2025 · Scorecard3rd of 5 | 1 of 1FY2025 · Scorecard1st of 5 | 0 of 1FY2025 · Scorecard3rd of 5 | 0 of 3FY2025 · Scorecard3rd of 5 | 1 of 1FY2025 · Scorecard1st of 5 | 0% passed5 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | —— | —— | 1.7%2026-Q2 · 13F5th of 5 | 88.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 5 | 50.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 5 | 104.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 5 | 33.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 5 | 50.9%5 ranked |
| Institutions holding (Better neither way: ranked highest first) | —— | —— | —— | 92026-Q2 · 13F5th of 5 | 1892026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 5 | 1192026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 5 | 1522026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 5 | 872026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 5 | 1195 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | —— | —— | —— | -2.8 pp2026-Q2 against 2026-Q1 · 13F3rd of 4 | -0.5 pp2026-Q2 against 2026-Q1 · 13F2nd of 4 | +18.8 pp2026-Q2 against 2026-Q1 · 13F1st of 4 | -3.4 pp2026-Q2 against 2026-Q1 · 13F4th of 4 | -1.6 pp4 ranked |
| Dividends | |||||||||
| Shareholder yield (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | 0.1%FY2025 · SEConly one with it15th7th | ———— | 0.1%— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Cassiopea SPA: How market caps are worked out; Atrys Health, S.A.: How market caps are worked out; Newron Pharmaceuticals: How market caps are worked out; Genenta Science S.P.A.: How market caps are worked out; ARS Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Fennec Pharmaceuticals Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; C4 Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Nautilus Biotechnology, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Cassiopea SPA | — | — | — |
| Atrys Health, S.A. | -29.6%FY2025 | 38th percentile in Healthcaremedian -7.7%, 674 companies | 6th percentile in Spainmedian 9.2%, 79 companies |
| Newron Pharmaceuticals | — | — | — |
| Genenta Science S.P.A. | — | — | — |
| ARS Pharmaceuticals, Inc. | -212.9%FY2025 | 15th percentile in Healthcaremedian -7.7%, 674 companies | 5th percentile in USAmedian 3.5%, 2,594 companies |
| Fennec Pharmaceuticals Inc. | -14.1%FY2025 | 44th percentile in Healthcaremedian -7.7%, 674 companies | 24th percentile in USAmedian 3.5%, 2,594 companies |
| C4 Therapeutics, Inc. | -320.5%FY2025 | 11th percentile in Healthcaremedian -7.7%, 674 companies | 4th percentile in USAmedian 3.5%, 2,594 companies |
| Nautilus Biotechnology, Inc. | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Cassiopea SPA | Atrys Health, S.A. | Newron Pharmaceuticals | Genenta Science S.P.A. | ARS Pharmaceuticals, Inc. | Fennec Pharmaceuticals Inc. | C4 Therapeutics, Inc. | Nautilus Biotechnology, Inc. |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | $159 MESEF1st | — | — | $84 MSEC2nd | $45 MSEC3rd | $36 MSEC4th | — |
| 2024 | — | $141 MESEF1st | — | — | $89 MSEC2nd | $48 MSEC3rd | $36 MSEC4th | — |
| 2023 | — | — | — | — | $0 MSEC3rd | $21 MSEC1st | $21 MSEC2nd | — |
| 2022 | — | — | — | — | $1 MSEC3rd | $2 MSEC2nd | $31 MSEC1st | — |
| 2021 | — | — | — | — | $6 MSEC2nd | — | $46 MSEC1st | — |
| 2020 | — | — | — | — | — | $0 MSEC | — | — |
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Cassiopea SPA#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Atrys Health, S.A.ATRY.MC · 🇪🇸 SpainSame industry: Biotechnology · Similar size: $312 M market cap against $380 M · Same region: Southern Europe · Ratios of the last two fiscal years on fileMarket cap $312 M (last known, Jan 5, 2024) · revenue $159 M (year to December 2025)91 of 100 (industry or sector 50 + size 29 + country 7 + figures on file 5)In the group
- Newron PharmaceuticalsNP5.F · 🇮🇹 ItalySame industry: Biotechnology · Similar size: $190 M market cap against $380 M · Same country: ItalyMarket cap $190 M (last known, Jan 5, 2024)90 of 100 (industry or sector 50 + size 26 + country 15)In the group
- Genenta Science S.P.A.GNTA · 🇮🇹 ItalySame industry: Biotechnology · 6.0× smaller by market cap · Same country: Italy · Ratios of the last two fiscal years on fileMarket cap $63 M (Aug 1, 2026)88 of 100 (industry or sector 50 + size 18 + country 15 + figures on file 5)In the group
- ARS Pharmaceuticals, Inc.SPRY · 🇺🇸 USASame industry: Biotechnology · Similar size: $375 M market cap against $380 M · Ratios of the last two fiscal years on fileMarket cap $375 M (Oct 28, 2026) · revenue $84 M (year to December 2025)85 of 100 (industry or sector 50 + size 30 + figures on file 5)In the group
- Fennec Pharmaceuticals Inc.FENC · 🇺🇸 USASame industry: Biotechnology · Similar size: $374 M market cap against $380 M · Ratios of the last two fiscal years on fileMarket cap $374 M (Oct 31, 2026) · revenue $45 M (year to December 2025)85 of 100 (industry or sector 50 + size 30 + figures on file 5)In the group
- C4 Therapeutics, Inc.CCCC · 🇺🇸 USASame industry: Biotechnology · Similar size: $391 M market cap against $380 M · Ratios of the last two fiscal years on fileMarket cap $391 M (Oct 27, 2026) · revenue $36 M (year to December 2025)85 of 100 (industry or sector 50 + size 30 + figures on file 5)In the group
- Nautilus Biotechnology, Inc.NAUT · 🇺🇸 USASame industry: Biotechnology · Similar size: $368 M market cap against $380 M · Ratios of the last two fiscal years on fileMarket cap $368 M (Oct 28, 2026)85 of 100 (industry or sector 50 + size 30 + figures on file 5)In the group
- Rezolute, Inc.RZLT · 🇺🇸 USASame industry: Biotechnology · Similar size: $398 M market cap against $380 M · Ratios of the last two fiscal years on fileMarket cap $398 M (Oct 28, 2026)85 of 100 (industry or sector 50 + size 30 + figures on file 5)+ Add
- Opus Genetics, Inc.IRD · 🇺🇸 USASame industry: Biotechnology · Similar size: $396 M market cap against $380 M · Ratios of the last two fiscal years on fileMarket cap $396 M (Oct 15, 2026) · revenue $14 M (year to December 2025)85 of 100 (industry or sector 50 + size 30 + figures on file 5)+ Add
- Nanobiotix S.A.NANO.PA · 🇫🇷 FranceSame industry: Biotechnology · Similar size: $363 M market cap against $380 M · Ratios of the last two fiscal years on fileMarket cap $363 M (last known, Jan 5, 2024) · revenue $33 M (year to December 2025)85 of 100 (industry or sector 50 + size 30 + figures on file 5)+ Add
- Editas Medicine, Inc.EDIT · 🇺🇸 USASame industry: Biotechnology · Similar size: $363 M market cap against $380 M · Ratios of the last two fiscal years on fileMarket cap $363 M (Oct 19, 2026) · revenue $41 M (year to December 2025)85 of 100 (industry or sector 50 + size 30 + figures on file 5)+ Add
- Hyloris Pharmaceuticals SAHYL.BR · 🇧🇪 BelgiumSame industry: Biotechnology · Similar size: $404 M market cap against $380 M · Ratios of the last two fiscal years on fileMarket cap $404 M (last known, Jan 5, 2024) · revenue $8 M (year to December 2025)85 of 100 (industry or sector 50 + size 30 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.